We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Cesca Therapeutics (KOOL) Stock Moves -0.73%: What You Should Know
Read MoreHide Full Article
Cesca Therapeutics (KOOL - Free Report) closed the most recent trading day at $0.38, moving -0.73% from the previous trading session. This move was narrower than the S&P 500's daily loss of 1.44%. Elsewhere, the Dow lost 1.27%, while the tech-heavy Nasdaq lost 2.06%.
Prior to today's trading, shares of the company had lost 3.55% over the past month. This has lagged the Medical sector's loss of 2.15% and the S&P 500's loss of 2.61% in that time.
Wall Street will be looking for positivity from KOOL as it approaches its next earnings report date. This is expected to be November 13, 2018. On that day, KOOL is projected to report earnings of -$0.10 per share, which would represent year-over-year growth of 58.33%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $2.97 million, down 3.26% from the year-ago period.
Investors might also notice recent changes to analyst estimates for KOOL. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. KOOL currently has a Zacks Rank of #3 (Hold).
Digging into valuation, KOOL currently has a Forward P/E ratio of 3.83. This valuation marks a discount compared to its industry's average Forward P/E of 33.56.
The Medical - Instruments industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 83, which puts it in the top 33% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Cesca Therapeutics (KOOL) Stock Moves -0.73%: What You Should Know
Cesca Therapeutics (KOOL - Free Report) closed the most recent trading day at $0.38, moving -0.73% from the previous trading session. This move was narrower than the S&P 500's daily loss of 1.44%. Elsewhere, the Dow lost 1.27%, while the tech-heavy Nasdaq lost 2.06%.
Prior to today's trading, shares of the company had lost 3.55% over the past month. This has lagged the Medical sector's loss of 2.15% and the S&P 500's loss of 2.61% in that time.
Wall Street will be looking for positivity from KOOL as it approaches its next earnings report date. This is expected to be November 13, 2018. On that day, KOOL is projected to report earnings of -$0.10 per share, which would represent year-over-year growth of 58.33%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $2.97 million, down 3.26% from the year-ago period.
Investors might also notice recent changes to analyst estimates for KOOL. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. KOOL currently has a Zacks Rank of #3 (Hold).
Digging into valuation, KOOL currently has a Forward P/E ratio of 3.83. This valuation marks a discount compared to its industry's average Forward P/E of 33.56.
The Medical - Instruments industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 83, which puts it in the top 33% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.